Clinical Trial Detail

NCT ID NCT02959463
Title Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

malignant pleural mesothelioma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.